CAMKK2
MOLECULAR TARGETcalcium/calmodulin dependent protein kinase kinase 2
CAMKK2 (calcium/calmodulin dependent protein kinase kinase 2) is targeted by 43 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting CAMKK2
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | alvocidib | 4.52 | 91 |
| 2 | foretinib | 4.34 | 76 |
| 3 | ponatinib | 4.26 | 70 |
| 4 | ceritinib | 4.19 | 65 |
| 5 | bosutinib | 4.08 | 58 |
| 6 | bi 2536 | 4.01 | 54 |
| 7 | midostaurin | 3.85 | 46 |
| 8 | brigatinib | 3.81 | 44 |
| 9 | abemaciclib | 3.66 | 38 |
| 10 | nintedanib | 3.61 | 36 |
| 11 | pelitinib | 3.50 | 32 |
| 12 | tae 684 | 3.43 | 30 |
| 13 | fedratinib | 3.40 | 29 |
| 14 | gilteritinib | 3.40 | 29 |
| 15 | at 7519 | 3.33 | 27 |
| 16 | sp 600125 | 3.22 | 24 |
| 17 | alectinib | 3.18 | 23 |
| 18 | jnj 7706621 | 3.09 | 21 |
| 19 | lestaurtinib | 3.04 | 20 |
| 20 | pacritinib | 3.04 | 20 |
| 21 | filgotinib | 3.04 | 20 |
| 22 | pf 03758309 | 3.00 | 19 |
| 23 | ruboxistaurin | 2.94 | 18 |
| 24 | danusertib | 2.94 | 18 |
| 25 | volasertib | 2.94 | 18 |
| 26 | k 252a | 2.83 | 16 |
| 27 | milciclib | 2.77 | 15 |
| 28 | pha 665752 | 2.71 | 14 |
| 29 | crenolanib | 2.71 | 14 |
| 30 | kw 2449 | 2.64 | 13 |
| 31 | ast 487 | 2.56 | 12 |
| 32 | lavendustin c | 2.48 | 11 |
| 33 | su 014813 | 2.20 | 8 |
| 34 | gsk 650394 | 2.20 | 8 |
| 35 | cyc 116 | 2.08 | 7 |
| 36 | enzastaurin | 2.08 | 7 |
| 37 | rg 547 | 2.08 | 7 |
| 38 | asp 3026 | 2.08 | 7 |
| 39 | pf 03814735 | 1.79 | 5 |
| 40 | ucn 01 | 1.79 | 5 |
| 41 | sp600125 | 1.10 | 2 |
| 42 | Axitinib | 0.69 | 1 |
| 43 | Crizotinib | 0.69 | 1 |
About CAMKK2 as a Drug Target
CAMKK2 (calcium/calmodulin dependent protein kinase kinase 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 43 compounds with documented CAMKK2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
CAMKK2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.